Innovative Biotechs Making Strides In Healthcare Sector: Alliqua, MiMedx, Organovo, Anacor Pharmaceuticals, Pfizer

CORAL SPRINGS, Florida, October 21, 2013 /PRNewswire/ --

Market news updates for October Biotech leaders: Alliqua Inc. (OTCQB: ALQA), MiMedx Group, Inc. (NASDAQ: MDXG), Organovo Holdings, Inc. (NYSE: ONVO) Anacor Pharmaceuticals (NASDAQ: ANAC) and Pfizer Inc. (NYSE: PFE)

Alliqua, Inc. (OTCQB: ALQA) Forges Ahead with Lidocaine Transdemal Patch Efforts:  A preclinical study commissioned by Alliqua ("the Company") concluded that the Company's investigational lidocaine transdermal patch compares favorably to the Lidoderm^® (Lidocaine patch 5%) patch that is currently on the market. The overall study results indicate that Alliqua's patch is able to deliver in the pig a slightly higher amount of lidocaine than Lidoderm and to reach maximum delivery within a comparable period. No skin irritation occurred with either the Alliqua transdermal patch or Lidoderm patch. The study concludes that further development could result in Alliqua creating a commercial lidocaine patch that could be a generic version of the Lidoderm patch or provide better drug delivery resulting in a 505 (b)(2) approval.  The study found that Alliqua's patch offers a higher peak plasma concentration (Cmax) of lidocaine than Lidoderm (4.96 +/- 1.16  ng/mL versus 3.03 +/- 1.92 ng/mL) and higher mean total area under the curve (AUCtotal) than the competing product (66.5 ng/mL-h versus 48.9 ng/mL-h). The mean period of peak concentration (Tmax) was 8.7 hours for Alliqua's patch versus 10.7 hours for Lidoderm.

To read the full press release, please go to: http://www.fnmprofiles.com/profiles-alqa.php

In further developments, the company has announced today that it has signed a distribution agreement with McKesson Medical-Surgical, by which their U.S. distribution network will stock and offer for sale Alliqua's SilverSeal^® and Hydress^® wound dressings to healthcare customers nationwide.David Johnson, Chief Executive Officer of Alliqua, said, "This encompasses expanding our distribution network within the U.S. for our SilverSeal^® and Hydress^® wound dressings. McKesson Medical-Surgical is one of the most well-known and respected health care distributors in the U.S. market. The expansion in distribution made possible by this agreement will assist customers with easy access to these products across the continuum of alternate site health care. "

To read the full press release, please go to: http://www.fnmprofiles.com/profiles-alqa.php

MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced that the Food and Drug Administration ("FDA") has rescheduled its meeting with the Company to take place on October 28, 2013. This meeting to discuss the recent Untitled Letter MiMedx received from the FDA was initially scheduled for October 16, 2013, but was postponed due to the recent partial Federal Government shutdown.

Organovo Holdings, Inc. (NYSE: ONVO) develops three-dimensional (3D) bioprinting technology for creating functional human tissues on demand for research and medical applications. ONVO's 3D NovoGen bioprinting technology works across various tissue and cell types, and allows for the placement of cells in desired pattern. It offers NovoGen MMX Bioprinter, a commercial hardware and software bioprinter platform to create tissues for bioprinting research and development. 

Anacor Pharmaceuticals (NASDAQ: ANAC) recently announced that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc. (Valeant), successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS), has issued an Interim Final Award in favor of Anacor, awarding Anacor $100 million in damages as well as all costs of the arbitration and reasonable attorney's fees. The parties may apprise the arbitrator of any issues not resolved in the Interim Final Award order within ten days, and responses to any such submission are due within fifteen days of the date of the Interim Final Award. If no submissions are made, this Interim Final Award will become final.

Pfizer Inc. (NYSE: PFE) announced recently top-line results from two phase 3b, placebo-controlled studies with Lyrica^® (pregabalin) Capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively. The fibromyalgia study, A0081275 met its primary endpoint, showing a reduction in pain associated with fibromyalgia in patients who were treated concurrently with antidepressant therapy for comorbid depression. Separately, the painful DPN study, A0081269 did not meet its co-primary endpoints by sufficiently reducing DPN pain and DPN pain on walking compared to placebo.

Gilead Sciences, Inc. (NASDAQ: GILD) recently announced three-year (144-week) efficacy and safety results from two pivotal Phase 3 studies (Studies 102 and 103) evaluating the once-daily single tablet regimen Stribild^® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) among treatment-naïve patients with HIV-1 infection. Data show that after three years of treatment, Stribild demonstrated comparable efficacy to two standard-of-care HIV regimens, Atripla^® (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Study 102 and a protease inhibitor-based regimen of ritonavir-boosted atazanavir plus Truvada^® (emtricitabine and tenofovir disoproxil fumarate) in Study 103. These data are being presented this week at the 14th European AIDS Clinical Society Conference (EACS) in Brussels, Belgium.

FinancialNewsMedia.com  is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com  for more details. Get an edge on the market with our Premium News Alerts   that are FREE for a limited time at http://www.financialnewsmedia.com/. Follow us on Facebook:  http://www.facebook.com/financialnewsmedia  and Twitter: http://twitter.com/FNMgroup.  Sign up for our FREE SMS News alerts delivered directly to your mobile phone by texting the word PRESS to 545454.  (SMS alerts are free, however data rates may apply, check your wireless plan for details.)

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  The companies that are discussed in this release may or may not have approved the statements made in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.

FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.  

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group, LLC